Literature DB >> 17804498

Interaction of decay-accelerating factor with coxsackievirus B3.

Susan Hafenstein1, Valorie D Bowman, Paul R Chipman, Carol M Bator Kelly, Feng Lin, M Edward Medof, Michael G Rossmann.   

Abstract

Many entero-, parecho-, and rhinoviruses use immunoglobulin (Ig)-like receptors that bind into the viral canyon and are required to initiate viral uncoating during infection. However, some of these viruses use an alternative or additional receptor that binds outside the canyon. Both the coxsackievirus-adenovirus receptor (CAR), an Ig-like molecule that binds into the viral canyon, and decay-accelerating factor (DAF) have been identified as cellular receptors for coxsackievirus B3 (CVB3). A cryoelectron microscopy reconstruction of a variant of CVB3 complexed with DAF shows full occupancy of the DAF receptor in each of 60 binding sites. The DAF molecule bridges the canyon, blocking the CAR binding site and causing the two receptors to compete with one another. The binding site of DAF on CVB3 differs from the binding site of DAF on the surface of echoviruses, suggesting independent evolutionary processes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804498      PMCID: PMC2169128          DOI: 10.1128/JVI.00931-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Fitting atomic models into electron-microscopy maps.

Authors:  M G Rossmann
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2000-10

Review 2.  Picornavirus-receptor interactions.

Authors:  Michael G Rossmann; Yongning He; Richard J Kuhn
Journal:  Trends Microbiol       Date:  2002-07       Impact factor: 17.079

3.  Complement regulation at the molecular level: the structure of decay-accelerating factor.

Authors:  P Lukacik; P Roversi; J White; D Esser; G P Smith; J Billington; P A Williams; P M Rudd; M R Wormald; D J Harvey; M D M Crispin; C M Radcliffe; R A Dwek; D J Evans; B P Morgan; R A G Smith; S M Lea
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-20       Impact factor: 11.205

4.  Interaction between echovirus 7 and its receptor, decay-accelerating factor (CD55): evidence for a secondary cellular factor in A-particle formation.

Authors:  R M Powell; T Ward; D J Evans; J W Almond
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Evidence for the direct involvement of the rhinovirus canyon in receptor binding.

Authors:  R J Colonno; J H Condra; S Mizutani; P L Callahan; M E Davies; M A Murcko
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor.

Authors:  Y He; P R Chipman; J Howitt; C M Bator; M A Whitt; T S Baker; R J Kuhn; C W Anderson; P Freimuth; M G Rossmann
Journal:  Nat Struct Biol       Date:  2001-10

7.  A cellular receptor of human rhinovirus type 2, the very-low-density lipoprotein receptor, binds to two neighboring proteins of the viral capsid.

Authors:  Emmanuelle Neumann; Rosita Moser; Luc Snyers; Dieter Blaas; Elizabeth A Hewat
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding.

Authors:  T M Karnauchow; S Dawe; D M Lublin; K Dimock
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

9.  A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts.

Authors:  Amanda D Stuart; Hannah E Eustace; Thomas A McKee; T D K Brown
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Characterization of early steps in the poliovirus infection process: receptor-decorated liposomes induce conversion of the virus to membrane-anchored entry-intermediate particles.

Authors:  Tobias J Tuthill; Doryen Bubeck; David J Rowlands; James M Hogle
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

View more
  27 in total

1.  Specificity of coxsackievirus B3 interaction with human, but not murine, decay-accelerating factor: replacement of a single residue within short consensus repeat 2 prevents virus attachment.

Authors:  Jieyan Pan; Lili Zhang; Lindsey J Organtini; Susan Hafenstein; Jeffrey M Bergelson
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Variations of coxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment.

Authors:  Steven D Carson; Nora M Chapman; Susan Hafenstein; Steven Tracy
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Molecular determinants of disease in coxsackievirus B1 murine infection.

Authors:  Javier O Cifuente; María F Ferrer; Carolina Jaquenod de Giusti; Wen-Chao Song; Víctor Romanowski; Susan L Hafenstein; Ricardo M Gómez
Journal:  J Med Virol       Date:  2011-09       Impact factor: 2.327

4.  Single amino acid changes in the virus capsid permit coxsackievirus B3 to bind decay-accelerating factor.

Authors:  Jieyan Pan; Bhargavi Narayanan; Shardule Shah; Joshua D Yoder; Javier O Cifuente; Susan Hafenstein; Jeffrey M Bergelson
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

Review 5.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

6.  The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with decay-accelerating factor (DAF) provide a new footprint of DAF on the virus surface.

Authors:  Joshua D Yoder; Javier O Cifuente; Jieyan Pan; Jeffrey M Bergelson; Susan Hafenstein
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

7.  Complement protective epitopes and CD55-microtubule complexes facilitate the invasion and intracellular persistence of uropathogenic Escherichia coli.

Authors:  Tanu Rana; Rafia J Hasan; Stella Nowicki; Mathura S Venkatarajan; Rajbir Singh; Petri T Urvil; Vsevolod Popov; Werner A Braun; Waldemar Popik; J Shawn Goodwin; Bogdan J Nowicki
Journal:  J Infect Dis       Date:  2013-11-20       Impact factor: 5.226

8.  A gene signature for post-infectious chronic fatigue syndrome.

Authors:  John W Gow; Suzanne Hagan; Pawel Herzyk; Celia Cannon; Peter O Behan; Abhijit Chaudhuri
Journal:  BMC Med Genomics       Date:  2009-06-25       Impact factor: 3.063

9.  Structural comparison of different antibodies interacting with parvovirus capsids.

Authors:  Susan Hafenstein; Valorie D Bowman; Tao Sun; Christian D S Nelson; Laura M Palermo; Paul R Chipman; Anthony J Battisti; Colin R Parrish; Michael G Rossmann
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

10.  Kinetic and structural analysis of coxsackievirus B3 receptor interactions and formation of the A-particle.

Authors:  Lindsey J Organtini; Alexander M Makhov; James F Conway; Susan Hafenstein; Steven D Carson
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.